European Society for Medical Oncology Congress (ESMO)

Continuing gefitinib after acquiring resistance to the TKI adds no clinical benefit in patients with EGFR-positive non-small-cell lung cancer, according to trial results presented at the 2014 ESMO Congress.

Almost three out of every four young oncologists in Europe may be experiencing burnout, according to data from the largest burnout survey conducted to date.

As part of our coverage of the 2014 ESMO meeting we discuss recent advances in the treatment of kidney, bladder, and testicular cancers.